Invo BioScience (INVO)
(Delayed Data from NSDQ)
$0.86 USD
-0.04 (-4.67%)
Updated Oct 18, 2024 03:58 PM ET
After-Market: $0.82 -0.04 (-4.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.86 USD
-0.04 (-4.67%)
Updated Oct 18, 2024 03:58 PM ET
After-Market: $0.82 -0.04 (-4.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -66% and 66.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -12.90% and 10.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Invo BioScience Inc. (INVO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Invo BioScience Inc. (INVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Invo BioScience Inc. (INVO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Invo BioScience Inc. (INVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 37.50% and 11.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Invo BioScience Inc. (INVO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invo BioScience Inc. (INVO) delivered earnings and revenue surprises of -20.00% and -13.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Invo BioScience Inc. (INVO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Invo BioScience Inc. (INVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invo BioScience Inc. (INVO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invo BioScience Inc. (INVO) delivered earnings and revenue surprises of 10.53% and -0.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Invo BioScience Inc. (INVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Invo BioScience Inc. (INVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for May 21st
by Zacks Equity Research
ATHM, INVO, FOUR, KRYS, and RMAX have been added to the Zacks Rank #5 (Strong Sell) List on May 21, 2021
New Strong Sell Stocks for April 16th
by Zacks Equity Research
VNET, ALTG, FPI, HALL, and INVO have been added to the Zacks Rank #5 (Strong Sell) List on April 16, 2021